The EPS beat of 26% vs consensus is largely mechanical given the tiny absolute base (-$0.57 vs -$0.77). The key catalyst is the randomized Phase 2 data for agenT-797 in ARDS expected H2 2026, a binary event in a large unmet need market. Monitor cash runway closely; with $9.5M and quarterly burn of ~$3.9M, the company will likely need additional financing before year-end 2026. The ATS presentation on May 20 could provide a near-term catalyst if data is positive.
INKT drugs
INKT drug pipeline →Price Chart
Executive Summary
MiNK Therapeutics reported Q1 2026 results with a net loss of $2.7M ($0.57 per share), beating consensus estimates of -$0.77 per share by 26%. The company advanced its lead iNKT cell therapy candidate agenT-797 into a randomized Phase 2 trial for acute lung injury, with preliminary data expected in H2 2026. Cash burn remains disciplined at $9.5M quarter-end, but the company continues to rely on at-the-market equity raises ($3.0M in Q1) and non-dilutive collaborations to fund operations.
Key Financial Metrics
Key Facts
- Net loss of $2.7M ($0.57 per share) vs $2.8M ($0.70 per share) in Q1 2025
- Cash and cash equivalents of $9.5M as of March 31, 2026, down from $13.4M at year-end 2025
- Repaid $5.2M Agenus convertible note during Q1 2026
- Raised $3.0M through at-the-market equity sales agreement in Q1 2026
- Initiated randomized Phase 2 trial for agenT-797 in severe acute lung injury/ARDS
- Preliminary Phase 2 data expected in second half of 2026
- Non-dilutive C-Further collaboration provides up to $1.1M for pediatric oncology program
- ATS conference presentation on agenT-797 in persistent infection scheduled for May 20, 2026
Financial Impact
Net loss improved slightly to $2.7M from $2.8M YoY; cash burn of ~$3.9M in Q1; $9.5M cash runway likely <12 months without additional financing
Risk Factors
- Cash runway of ~$9.5M may only fund operations through ~2-3 quarters without additional capital raises
- Phase 2 ARDS trial is early-stage with binary readout risk; no approved pharmacologic therapies exist in this indication
- Reliance on at-the-market equity sales for funding creates ongoing dilution for existing shareholders
- Clinical-stage biotech with no approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-225369 |
| Document: inkt-ex99_1.htm | 0001193125-26-225369 |
| Document: 0001193125-26-225369-index-headers.html | 0001193125-26-225369 |
| Document: 0001193125-26-225369-index.html | 0001193125-26-225369 |
| Document: 0001193125-26-225369.txt | 0001193125-26-225369 |
| 8-K Data (Synthetic) | 0001193125-26-225369 |
Track record
21 reports on INKT
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers